|
|
Volumn 7, Issue 1, 2006, Pages 2-3
|
|
Keynote comment: Reimbursement for molecularly targeted anticancer agents [1]
a
b
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
BEVACIZUMAB;
FLUOROURACIL;
FOLINIC ACID;
GEFITINIB;
OXALIPLATIN;
CANCER;
CANCER SURVIVAL;
COLORECTAL CANCER;
COST EFFECTIVENESS ANALYSIS;
DRUG APPROVAL;
DRUG RESEARCH;
DRUG TARGETING;
GENE MUTATION;
HEALTH CARE ACCESS;
HEALTH CARE SYSTEM;
HUMAN;
LETTER;
LUNG SMALL CELL CANCER;
PRIORITY JOURNAL;
REIMBURSEMENT;
ANTINEOPLASTIC AGENTS;
COST-BENEFIT ANALYSIS;
DRUG APPROVAL;
DRUG COSTS;
ECONOMICS, PHARMACEUTICAL;
GENES, NEOPLASM;
HUMANS;
INSURANCE, HEALTH, REIMBURSEMENT;
MOLECULAR BIOLOGY;
NEOPLASMS;
|
|
EID: 29744462010
PISSN: 14702045
EISSN: None
Source Type: Journal
DOI: 10.1016/S1470-2045(05)70512-X Document Type: Letter |
|
Times cited : (3)
|
|
References (4)
|
